Andrew Justin Radcliffe Porter

Part of Bioven Holdings Sdn. The company is based in Aberdeen, UK. The British company manufactures and develops pharmaceutical products. Bhd., In3Bio Research Ltd. is a pharmaceutical company founded in 2009.

Haptogen Ltd. manufactures biopharmaceuticals products. The company was founded by Jim Reid in 2002 and is headquartered in Aberdeen, UK.

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

Cytosystems Ltd. develops advanced diagnostic techniques for cancer. Its products include BladderLight, a urine-based screening and diagnostic solution for the detection of cancer of the bladder and the prostate. The company was founded by David Galloway in 2006 and is headquartered in Aberdeen, the United Kingdom.

Antoxis Ltd. designs and develops synthesis therapeutic antioxidants. The firm also develops innovative approaches for the treatment of neurodegenerative conditions, cardiovascular disease, cancer and inflammatory disorders through its mitochondrial-targeted, redox technology platform. The company was founded by Andrew Scott Johnstone and Donald Barton Mcphail in March 2005 and is headquartered in Aberdeen, the United Kingdom.

Grampian Biopartners Ltd. specializes in seed funding early stage life-science companies. It also offers consultancy services, such as technical and commercial due diligence. The firm focuses on covers immuno-diagnostics and devices, immuno-technology, biologic drug discovery. The company was founded by Andrew Justin Radcliffe Porter, Gillian Broadbent and Keith Charlton in March 2008 and is headquartered in Aberdeen, the United Kingdom.

Elasmogen Ltd. develops soloMER products for treatment of auto-immune mediated and inflammatory diseases. The company is headquartered in Aberdeen, the United Kingdom.